arrow
D

David S. Ziegler

copenhagen university hospital
H指数:45
被引数:8,572

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Precision-guided therapy in H3K27-altered diffuse midline glioma

H3K27-改变的弥漫性中线胶质瘤中的精准导向疗法

2026-05-190
OAAI
Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial
2026-04-011
PRE
Combined inhibition of FACT and BET disrupts transcription to suppress tumor growth in mouse models of diffuse midline glioma

联合抑制FACT和BET破坏转录以抑制弥漫性中线胶质瘤小鼠模型的肿瘤生长

2026-01-140
PRE
TIP-30. Molecularly-guided phase 2 umbrella trial for children and young adults with newly-diagnosed high-grade glioma (HGG) including diffuse intrinsic pontine glioma (DIPG): CONNECT TarGeT (Targeted pediatric HGG therapy) trial in progress

TIP-30. 分子引导的针对新诊断的高级别胶质瘤(HGG,包括弥漫性内生性脑桥胶质瘤(DIPG)的儿童及青少年患者的二期伞式临床试验:正在进行的CONNECT TarGeT(靶向儿科HGG疗法)试验。

2025-11-110
OA
Clinical stability following tovorafenib treatment in relapsed/refractory pediatric low-grade glioma: updated results from the phase 2 FIREFLY-1 trial

托伐拉芬治疗后复发/难治性儿童低级别胶质瘤的临床稳定性:更新来自2期FIREFLY-1试验的结果

2025-11-010
OAAI
The development of ACT001 with Mcl-1 inhibitors as a novel combination therapy for the treatment of paediatric diffuse midline glioma

ACT001与Mcl-1抑制剂联合开发作为一种新型联合疗法,用于治疗儿童弥漫性中线胶质瘤

2025-11-010
OAAI
CHROMATIN REMODELING WITH COMBINED FACT AND BET INHIBITION DISRUPTS ONCOGENIC TRANSCRIPTION IN DIFFUSE MIDLINE GLIOMA

联合FACT和BET抑制的染色质重塑破坏弥漫性中线胶质瘤中的致癌转录

2025-11-010
OAAI
Biological Medicines for Diffuse Intrinsic Pontine Gliomas (DIPG) Eradication (BIOMEDE). An International Randomized Phase II Biomarker-driven Platform Trial Comparing Three Targeted Therapies in Combination with Radiotherapy

弥漫性内生性脑桥胶质瘤(DIPG)清除的生物制剂(BIOMEDE)。一项国际性、随机化、II期、生物标志物驱动的平台试验,比较三种靶向疗法联合放射治疗的效果。

2025-11-010
OAAI
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial (vol 30, pg 207, 2024)

复发/难治性小儿低度神经胶质瘤中的II型RAF抑制剂tovorafenib: 2期FIREFLY-1试验 (第30卷,207页,2024)

2025-04-160
OA
The Super Enhancer-Driven Long Noncoding RNA PRKCQ-AS1 Promotes Neuroblastoma Tumorigenesis by Interacting With MSI2 Protein and Is Targetable by Small Molecule Compounds

超增强子驱动的长链非编码RNA PRKCQ-AS1通过与其SI2蛋白相互作用促进神经母细胞瘤肿瘤发生,且可被小分子化合物靶向。

2025-03-180
OAAI
Germline analysis of an international cohort of pediatric diffuse midline glioma patients

对国际队列儿童弥漫性中线胶质瘤患者的生殖系分析

2025-03-120
PRE
High-throughput in vitro drug screening and in vivo studies identify fenretinide as a brain-penetrant DMG therapeutic

高通量体外药物筛选和体内研究将fenretinide确定为一种能够穿透血脑屏障的DMG治疗药物。

2025-02-120
PRE
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial

在FIREFLY-1试验中,托瓦雷芬尼(tovorafenib)这种II型RAF抑制剂对复发性/难治性视神经通路胶质瘤患儿的放射学和视觉反应。

2024-12-190
PRE